Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
Name (Synonyms) | Correlation | |
---|---|---|
drug2460 | Placebo (saline) Wiki | 1.00 |
drug2953 | Saliva sample collection Wiki | 0.71 |
drug295 | Assessment of work-related stress Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D002055 | Burnout, Professional NIH | 0.33 |
D000077062 | Burnout, Psychological NIH | 0.23 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.04 |
Name (Synonyms) | Correlation |
---|
Navigate: Correlations HPO
There is one clinical trial.
This study is designed to evaluate three dose levels of Anti-SARS-CoV-2 Immunoglobulin Intravenous (Human) (COVID-HIGIV) for safety and pharmacokinetics (PK) in healthy adults. Two cohorts of healthy adult subjects will be enrolled into the study, cohort A (single dose) and cohort B (repeat dose); cohort A enrollment will be initiated first, and after the enrolled cohort A subjects complete up to 28 days of safety and PK follow-up and an interim analysis of that data has been completed, cohort B enrollment will be initiated.
Description: Incidence and severity of AEs up to 3 days post-dosing.
Measure: Number of Subjects with Adverse Events (AEs) post-dosing Time: Day 1 through Day 3Description: Incidence and severity of AEs that led to discontinuation or temporary suspension of IV infusion.
Measure: Number of Subjects with Adverse Events that Led to Discontinuation or Temporary Suspension of IV Infusion Time: 0 hours to 2.5 hoursDescription: Incidence and severity of AEs up to 84 days after a single IV infusion.
Measure: Number of Subjects with AEs after a Single IV Infusion Time: Day 1 through Day 85Description: Incidence and severity of SAEs up to 84 days after a single IV infusion.
Measure: Number of Subjects with SAEs after a Single IV Infusion Time: Day 1 through Day 85Description: Incidence and Severity of AEs up to 56 days after a repeat IV infusion.
Measure: Number of Subjects with AEs after a Repeat IV Infusion Time: Day 1 through Day 57Description: Incidence and Severity of SAEs up to 56 days after a repeat IV infusion.
Measure: Number of Subjects with SAEs after a Repeat IV infusion Time: Day 1 through Day 57Description: The area under the concentration-time curve from time 0 to the last quantifiable concentration after a single dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of SARS-CoV-2 antibodies after a single dose of COVID-HIGIV Time: Day 1 through Day 85Description: AUC0-t plus the additional area extrapolated to infinity after a single dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of area under the concentration-time (AUC) from time 0 to the last quantifiable concentration (AUC0-t) of SARS-CoV-2 antibodies plus the additional area extrapolated to infinity (AUC0-inf) after a single dose of COVID-HIGIV Time: Day 1 through Day 85Description: AUC from time 0 to 14 days after a single dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 14 days (AUC0-14d) after a single dose of COVID-HIGIV Time: Day 1 through Day 15Description: AUC from time 0 to 28 days after a single dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 28 days (AUC0-28d) after a single dose of COVID-HIGIV Time: Day 1 through Day 29Description: The Cmax observed after a single dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of maximum observed concentration (Cmax) of SARS-CoV-2 antibodies observed after a single dose of COVID-HIGIV Time: Day 1 through Day 85Description: Time at which Cmax occurs after a single dose of COVID-HIGIV at each dose level.
Measure: Pharmacokinetics parameter of time at which Cmax occurs after a single dose of COVID-HIGIV Time: Day 1 through Day 85Description: The observed trough concentration 28 days after a single dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of trough concentration of SARS-CoV-2 antibodies observed 28 days after a single dose (Cmin28d) of COVID-HIGIV Time: Day 1 through Day 29Description: The terminal elimination rate constant after a single dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of terminal elimination constant after a single dose of COVID-HIGIV Time: Day 1 through Day 85Description: The apparent terminal elimination half-life after a single dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of apparent terminal elimination half-life after a single dose of COVID-HIGIV Time: Day 1 through Day 85Description: The systemic clearance after a single dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of systemic clearance after a single dose of COVID-HIGIV Time: Day 1 through Day 85Description: The volume of distribution after a single dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of volume of distribution after a single dose of COVID-HIGIV Time: Day 1 through Day 85Description: The AUC from time 0 to 14 days after the initial dose and after the repeat dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 14 days (AUC0-14d) after initial and repeat dose of COVID-HIGIV Time: Day 1 to Day 15, Day 29 to Day 43Description: The AUC from time 0 to 28 days after the initial dose and after the repeat dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of area under the concentration-time curve (AUC) from time 0 to 28 days (AUC0-28d) after initial and repeat dose of COVID-HIGIV Time: Day 1 to Day 29, Day 29 to Day 57Description: Cmax observed after the initial dose and after the repeat dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of maximum observed concentration (Cmax) of SARS-CoV-2 antibodies observed after initial dose and repeat dose of COVID-HIGIV. Time: Day 1 through Day 85Description: The time at which Cmax occurs after the initial dose and after the repeat dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of time at which Cmax occurs after initial and repeat dose of COVID-HIGIV Time: Day 1 through Day 85Description: The observed trough concentration 28 days after the initial dose and after the repeat dose of COVID-HIGIV.
Measure: Pharmacokinetics parameter of trough concentration of SARS-CoV-2 antibodies observed 28 days after initial and repeat dose of COVID-HIGIV Time: Day 1 through Day 57Description: Accumulation ratios expressed as ratios of AUC0-14d, AUC0-28d, Cmin28d (trough) and Cmax after repeat dose over initial dose of COVID-HIGIV
Measure: Pharmacokinetics parameter of accumulation ratios after repeat dose over initial dose of COVID-HIGIV Time: Day 1 through Day 85Alphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports